Keywords: interest, expenses, currency, hit, sb, results, smithkline
Interest Expenses, Currency Hit SB's Results
Article | 31 July 1995
SmithKline Beecham has reported second-quarter 1995 sales from continuing operations at L31.64 billion ($2.61 billion), a rise of 12% on the like, year-earlier ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
